The radionuclide molecular imaging and therapy of neuroendocrine tumors

Current Cancer Drug Targets

Volumn 5, Issue 2, 2005, Pages 139-148

  Li, Shuren ^a   Beheshti, Mohsen ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Imaging; Molecular; Neuroendocrine tumors; Radionuclide; Treatment

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 6 FLUORODOPA F 18; BIOGENIC AMINE; BOMBESIN; CHOLECYSTOKININ B RECEPTOR; FLUORODEOXYGLUCOSE F 18; LIPOCORTIN 5; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SUCCIMER TC 99M; TETROFOSMIN TC 99M; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANGIOGRAPHY; ARTICLE; BLOOD EXAMINATION; CANCER LOCALIZATION; CHEMICAL ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; ECHOGRAPHY; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; SCINTIGRAPHY; SCINTISCANNING; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; THYROID MEDULLARY CARCINOMA; URINALYSIS; VASOACTIVE INTESTINAL PEPTIDE RECEPTOR SCINTIGRAPHY;

ANIMALS; HUMANS; NEUROENDOCRINE TUMORS; RADIOIMMUNOTHERAPY; RADIONUCLIDE IMAGING;

EID: 16844369124     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009053202054     Document Type: Article

References (97)

1. Bombardieri, E.; Maccauro, M.; De Deckere, E.; Savelli, G.; Chiti, A. Nuclear medicine imaging of neuroendocrine tumours. Ann. Oncol. 2001, 12 Suppl., S51-S61.
2. Chatal, J. F.; Le Bodic, M. F.; Kraeber-Bodere, F.; Rousseau, C.; Resche, I. Nuclear medicine applications for neuroendocrine tumors. World J. Surg. 2000, 24, 1285-1289.
3. Öberg K. State of the art and future prospects in the management of neuroendocrine tumors. QJNM 2000, 44, 3-12.
4. Caplin, M. E.; Buscombe, J. R.; Hilson, A. J. Carcinoid tumour. Lancet 1998, 352, 799-805.
5. Seregni, E.; Ferrari, L.; Stivanello, M.; Dogliotti, L. Laboratory tests for neuroendocrine tumours. QJNM 2000, 44, 22-41.
6. Kaltsas, G.; Rockall, A.; Papadogias, D.; Reznek, R.; Grossman, A. B. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur. J. Endocrinol. 2004, 151, 15-27.
7. Shapiro, B.; Copp, J. E.; Sisson, J. C.; Eyre, P. L.; Wallis, J.; Beierwaltes, W. H. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J. Nucl. Med. 1985, 26, 576-585.
8. Shapiro, B.; Fig, L. M.; Gross, M. D.; Khafagi, F. Radiochemical diagnosis of adrenal disease. Crit. Rev. Clin. Lab. Sci. 1989, 27, 265-298.
9. Berglund, A. S.; Hulthen, U. L.; Manhem, P. Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of phaechromocytomas. J. Inter. Med. 2001, 249, 247-251.
10. Castellani, M. R.; Chiti, A.; Seregni, E.; Bombardieri, E. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. QJNM 2000, 44, 77-87.
11. Nakajo, M.; Shapiro B.; Copp, J. The normal and abnormal distribution of the adrenomedullary imaging agent m-(113I) lodobenzylauanidine (I-131-MIBG) in man: evaluation by scintigraphy. J. Nucl. Med. 1983, 24, 672-682.
12. Shapiro, B.; Sisson, J. C.; Wieland, D. M.; Mangner, T. J.; Zempel, S. M.; Mudgett, E. Radiopharmaceutical therapy of malignant pheochromocytoma with 131I-Metaiodobenzylguanidine: Results from ten years of experience. J. Nucl. Biol. Med. 1991, 35, 269-276.
13. Shapiro, B. Summary, conclusions, and future directions of [131I]metaiodobenzylguanidine therapy in the treatment of neural crest tumors. J. Nucl. Biol. Med. 1991, 35, 357-363.
14. Shapiro, B.; Sisson, J. C.; Shulkin, B. L.; Gross, M. D.; Zempel, S. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuroendocrine tumors. OJNM 1995, 39(Suppl. 1), 3-8.
15. Ott, R. J.; Tait, D.; Flower, M. A.; Babich, J. W. Lambrecht, R. M. Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography. Br. J. Radiol. 1992, 65,787-791.
16. Solanki, K. K.; Bomanji, J.; Moyes, J.; Mather, S. J.; Trainer P. J.; Britton K. E. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobezylguanidine (MIBG). Nucl. Med. Comm. 1992, 13, 513-521.
17. Khafagi, F. A.; Shapiro, B.; Fig, L. M. Labetolol reduces 131I-MIBG uptake by pheochromocytoma and normal tissue. J. Nucl. Med. 1989, 30, 481-489.
18. Patel, Y.C. Molecular pharmacology of somatostatin receptor subtypes. J. Endocrinol. Invest. 1997, 20, 348-367.
19. Patel, Y. C. Somatostatin and its receptor family. Front Neuroendocrinol. 1999, 20, 157-198.
20. Reubi, J. C.; Schar, J. C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J. S.; Macke, H. R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic andradiotherapeutic use. Eur. J. Nucl. Med. 2000, 27, 273-282.
21. Reubi, J. C.; Schaer, J. C.; Waser, B.; Mengod, G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 1994, 54, 3455-3459.
22. Reubi, J. C.; Schaer, J. C., Waser, B.; Hoeger, C.; Rivier, J. A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors. Eur. J. Pharmacol. 1998, 345, 103-110.
23. Krenning, E. P.; de Jong, M.; Kooij, P. P.; Breeman, W. A.; Bakker, W. H.; de Herder, W. W.; van Eijck, C. H.; Kwekkeboom, D. J.; Jamar, F.; Pauwels, S.; Valkema, R. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann. Oncol. 1999, 10 (Suppl. 2), S23-S29.
24. Virgolini, I.; Angelberger, P.; Li, S.; Yang, Q.; Kurtaran, A.; Raderer, M.; Neuhold, N.; Kaserer, K.; Leimer, M.; Peck-Radosavljevic, M.; Scheithauer, W.; Niederle, B.; Eichler, H. G.; Valent, P. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), l23I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT. Eur. J. Nucl. Med. 1996, 23, 1388-1399.
25. Virgolini, I.; Traub, T.; Leimer, M.; Novotny, C.; Pangerl, T.; Ofluoglu, S.; Halvadjieva, E.; Smith-Jones, P.; Flores, J.; Li, S. R.; Angelberger, P.; Havlik, E.; Andreae, F.; Raderer, M.; Kurtaran, A.; Niederle, B.; Dudczak, R. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. QJNM 2000, 44, 50-58.
26. Breeman, W. A.; Kwekkeboom, D. J.; Kooij, P. P.; Bakker, W. H.; Hofland, L. J.; Visser, T. J.; Ensing, G. J.; Lamberts, S. W.; Krenning, E. P. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J. Nucl. Med. 1995, 36, 623-627.
27. Krenning, E. P.; Kwekkeboom, D. J.; Bakker, W. H.; Breeman, W. A.; Kooij, P. P.; Oei, H. Y.; van Hagen, M.; Postema, P. T.; de Jong, M.; Reubi J. C. Somatostatin receptor scintigraphy with 111In-DTPA-D-Phe1- and 123I-Tyr3-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 1993, 20, 716-731.
28. Kwekkeboom, D. J.; Kooij, P. P.; Bakker, W. H.; Macke, H. R.; Krenning, E. P. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J. Nucl. Med. 1999, 40, 762-767.
29. Krenning, E. P.; Bakker, W. H.; Breeman, W. A.; Koper, J. W.; Kooij, P. P.; Ausema, L.; Lameris, J. S.; Reubi, J. C.; Lamberts, S. W. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989, 1, 242-244.
30. Virgolini, I.; Patri, P.; Novotny, C.; Traub, T.; Leimer, M.; Fuger, B.; Li, S. R.; Angelberger, P.; Raderer, M.; Wogritsch, S.; Kurtaran, A.; Kletter, K.; Dudczak, R. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann. Oncol. 2001, 12(Suppl. 2), S41-S45.
31. Kwekkeboom, D. J.; Kooij, P. P.; Bakker, W. H.; van der Pluijm, M. E.; Srinivasan, A.; Erion, J.; Schmidt, M.; Bugaj, J.; de Jong, M.; Krenning, E. P. Lu-177-DOTA-Tyr3-octreotate: comparison with In-111-DTPA-octreotide in patients. Eur. J. Nucl. Med. 2001, 28, 1319-1325.
32. Breeman, W. A.; de Jong, M.; Kwekkeboom, D. J.; Valkema, R.; Bakker, W. H.; Kooij, P. P.; Visser, T. J.; Krenning, E. P. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur. J. Nucl. Med. 2001, 28, 1421-1429.
33. 86Y-DOTA0)-D-Phe1-Tyr3- octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur. J. Nucl Med Mol. Imaging 2003, 30, 510-518.
34. Anderson, C. J.; Dehdashti, F.; Cutler, P. D.; Schwarz, S. W.; Laforest, R.; Bass, L. A.; Lewis, J. S.; McCarthy, D. W. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med. 2001, 42, 213-221.
35. Henze, M.; Schuhmacher, J.; Dimitrakopoulou-Strauss, A.; Strauss, L. G.; Macke, H. R.; Eisenhut, M.; Haberkorn, U. Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC-PET. Eur. J. Nucl Med. Mol. Imaging 2004, 31, 466.
36. Schottelius, M.; Poethko, T.; Herz, M.; Reubi, J. C.; Kessler, H.; Schwaiger, M.; Wester, H. J. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin. Cancer Res. 2004, 10, 3593-3606.
37. Kwekkeboom, D. J.; Hoff, A. M.; Lamberts, S. W.; Oei, H. Y.; Krenning, E. P. Somatostatin analogue scintigraphy: a simple and sensitive method for the in vivo visualization of Merkel cell tumors and their metastases. Arch. Dermatol. 1992, 128, 818-821.
38. Durani, B.K.; Klein, A.; Henze, M.; Haberkorn, U.; Hartschuh, W. Somatostatin analogue scintigraphy in Merkel cell tumours. Br. J. Dermatol. 2003, 148, 1135-1140.
39. Moody, T. W.; Hill, J. M.; Jensen, R. T. VIP as a trophic factor in the CNS and cancer cells. Peptides 2003, 24, 163-177.
40. Reubi, J. C.; Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 781-793.
41. Virgolini, I.; Raderer, M., Kurtaran, A.; Angelberger, P.; Banyai, S.; Yang, Q.; Li, S.; Banyai, M.; Pidlich, J.; Niederle, B.; Scheithauer W.; Valent P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med. 1994, 331, 1116-1121.
42. Virgolini, I.; Kurtaran, A.; Raderer, M.; Leimer, M.; Angelberger, P.; Havlik, E.; Li, S.; Scheithauer, W.; Niederle, B.; Valent, P.; Vasoactive intestinal peptide receptor scintigraphy. J. Nucl. Med. 1995, 36, 1732-1739.
43. Thakur, M. L.; Marcus, C. S.; Saeed, S.; Pallela, V.; Minami, C.; Diggles, L.; Le Pham, H.; Ahdoot, R.; Kalinowski, E. A. 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J. Nucl Med. 2000, 41, 107-110.
44. Eriksson, B.; Bergstrom, M.; Orlefors, H.; Sundin, A.; Oberg, K.; Langstrom, B. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. QJNM 2000, 44, 68-76.
45. 18F- fluorodeoxyglucose positron emission tomography in small-cell lung cancer. Semin. Nucl. Med. 2002, 32, 272-275.
46. Adams, S.; Baum, R.; Rink, T.; Schumm-Drager, P. M.; Usadel, K. H.; Hor, G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur. J. Nucl. Med. 1998, 25, 79-83.
47. Pasquali, C.; Rubello, D.; Sperti, C.; Gasparoni, P.; Liessi, G.; Chierichetti, F.; Ferlin, G.; Pedrazzoli, S. Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J. Surg. 1998, 22, 588-592.
48. Scanga, D. R.; Martin, W. H.; Delbeke, D. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin. Nucl. Med. 2004, 29, 86-90.
49. Sundin, A.; Eriksson, B.; Bergstrom, M.; Langstrom, B., Oberg, K.; Orlefors, H. PET in the diagnosis of neuroendocrine tumors. Ann. NY Acad. Sci. 2004, 1014, 246-257.
50. Gupta, N. C.; Maloof, J.; Gunel, E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J. Nucl. Med. 1996, 37, 943-948.
51. Orlefors, H.; Sundin, A.; Ahlstrom, H.; Bjurling, P.; Bergstrom, M.; Lilja, A.; Langstrom, B.; Oberg, K.; Eriksson, B. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J. Clin. Oncol. 1998, 16, 2534-2541.
52. 18F DOPA whole body PET-initial results. Radiology 2002, 222, 507-512.
53. Jacob, T.; Grahek, D.; Younsi, N.; Kerrou, K.; Aide, N.; Montravers, F.; Balogova, S.; Colombet, C.; De Beco, V.; Talbot, J. N. Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 1266-1269.
54. Wank, S. A. G protein-coupled receptors in gastrointestinal physiology. 1. CCK receptors: an exemplary family. Am. J. Physiol. 1998, 274, G607-G613.
55. Reubi, J. C.; Schaer, J. C.; Waser, B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997, 57, 1377-1386.
56. Reubi, J. C.; Waser, B. Unexpected high incidence of cholecystokinin-B/ gastrin receptors in human medullary thyroid carcinomas. Int. J. Cancer 1996, 67, 644-647.
57. Behr, T. M.; Jenner, N.; Radetzky, S.; Behe, M.; Gratz, S., Yucekent, S.; Raue, F.; Becker, W. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur. J. Nucl. Med. 1998, 25, 424-430.
58. Behr, T. M.; Behe, M.; Angerstein, C.; Gratz, S.; Mach, R.; Hagemann, L.; Jenner, N.; Stiehler, M.; Frank-Raue, K.; Raue, F.; Becker, W. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin. Cancer Res. 1999, 5(suppl), 3124s-3138s.
59. Behe, M.; Becker, W.; Gotthardt, M.; Angerstein, C.; Behr, T. M. Improved kinetic stability of DTPA-DGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 1140-1146.
60. Reubi, J. C.; Waser, B.; Schaer, J. C.; Laederach, U.; Erion, J.; Srinivasan, A.; Schmidt M. A.; Bugaj, J. E. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur. J. Nucl. Med. 1998, 25, 481-490.
61. Kwekkeboom, D. J.; Bakker, W. H.; Kooij, P. P.; Erion, J.; Srinivasan, A.; de Jong, M.; Reubi, J. C.; Krenning, E. P. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur. J. Nucl. Med. 2000, 27, 1312-1317.
62. Behr, T. M.; Behe, M. P. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin. Nucl. Med. 2002, 32, 97-109.
63. Ohta, H.; Yamamoto, K.; Endo, K.; Mori, T.; Hamanaka, D.; Shimazu, A.; Ikekubo, K.; Makimoto, K.; Iida, Y.; Konishi, J. A. new imaging agent for medullary carcinoma of the thyroid. J. Nucl. Med. 1984, 25, 323-325.
64. Takekawa, H.; Shinano, H.; Tsukamoto, E.; Koseki, Y.; Ikeno, T.; Miller, F.; Kawakami, Y. Technetium 99m tetrofosmin imaging in lung cancer: relationship with histopathology. Ann. Nucl. Med. 1999, 73, 71-75.
65. Delaloye, A. B.; Delaloye, B. Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion? Eur. J. Nucl. Med. 1995, 22, 571-580.
66. Raderer, M.; Becherer, A.; Kurtaran, A.; Angelberger, P.; Li, S.; Leimer, M.; Weinlaender, G.; Kornek, G.; Kletter, K.; Scheithauer, W.; Virgolini I. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy. J. Nucl. Med. 1996, 37, 1480-1487.
67. Behr, T. M.; Gratz, S.; Markus, P. M.; Dunn, R. M.; Hufner, M.; Schauer, A.; Fischer, M.; Munz, D. L.; Becker, H.; Becker, W. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer 1997, 50(Suppl. 12), 2436-2457.
68. Breeman, W. A.; De Jong, M.; Bernard, B. F.; Kwekkeboom, D. J.; Srinivasan, A.; van der Pluijm, M. E.; Hofland, L. J.; Visser, T. J.; Krenning, E. P. Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int. J. Cancer 1999, 83, 657-663.
69. Krenning, E. P.; Kwekkeboom, D. J.; Valkema, R.; Pauwels, S.; Kvols, L. K.; De Jong, M. Peptide receptor radionuclide therapy. Ann. NY Acad. Sci. 2004, 1014, 234-245.
70. DuBois, S. G.; Messina, J.; Maris, J. M.; Huberty, J.; Glidden, D. V.; Veatch, J.; Charron, M.; Hawkins, R.; Matthay, K. K. Hematologic toxicity of high-dose iodine-131-metaiodobenzyl-guanidine therapy for advanced neuroblastoma. J. Clin. Oncol. 2004, 22, 2452-2460.
71. Macey, D. J.; Denardo, S. J.; Denardo, G. L.; Goodnight, J. K.; Unger, M. W. Uptake of indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma. Am. J. Physiol. Imaging 1988, 3, 1-6.
72. Stein, R.; Chen, S.; Reed, L.; Richel, H.; Goldenberg, D. M. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine. Cancer 2002, 94, 51-61.
73. 131I-Metaiodobenzylguanidine in the treatment of neuroblastoma. Med. Pediatr. Oncol. 1998, 37, 22-26.
74. 131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status. Med. Pediatr. Oncol. 1999, 32, 427-431.
75. Shapiro, B.; Fig, L. M. General principles and perspectives of cancer therapy with radiopharmaceuticals. J. Nucl. Med. Allied Sci. 1990, 34, 260-264.
76. Sisson, J. C.; Shapiro, B.; Hutchinson, R. J.; Carey, J. E.; Zasadny, K. R.; Zempel, S. A.; Normolle, D. P. Pedictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine. Eur. J. Nucl. Med. 1994, 21, 46-52.
77. Krempf, M.; Lumbroso, L.; Mornex, R.; Brendel, A. J.; Wemeau, J. L.; Delisle, M. L.; Aubert, B.; Carpentier, P.; Fleury-Goyon, M. C.; Gibold, C. Use of 131I-metaiodoenzylguandidine in the treatment of malignant phaeochromocytoma. J. Clin. Endocrinol. Metab. 1991, 72, 455-461.
78. Lewington, V. J.; Zianovic, M. A.; Tristam, M.; McEwan, A. J.; Ackery, D. M. Radiolabeled metaiodobenzylguanidine targeted raidiotherapy for malignant pheochromocytoma. J. Nuc. Biol. Med. 1991, 35, 280-283.
79. Loh, K. C.; Fitzgerald, P. A.; Matthay, K. K.; Yeo, P. P. B.; Price, D. C. The treatment of malignant phaeochromocytoma with Iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 patients. J. Endocrinol. Invest. 1997, 20, 648-658.
80. Grotzinger, C.; Wiedenmann, B. Somatostatin receptor targeting for tumor imaging and therapy. Ann. NY Acad. Sci. 2004, 1014, 258-264.
81. de Jong, M.; Breeman, W. A.; Bernard, B. F.; Bakker, W. H.; Schaar, M.; van Gameren, A.; Bugaj, J. E.; Erion, J.; Schmidt, M.; Srinivasan, A.; Krenning, E. P. 177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int. J. Cancer 2001, 92, 628-633.
82. Hammond, P. J.; Wade, A. F.; Gwilliam, M. E.; Peters, A. M.; Myers, M. J.; Gilbey, S. G.; Bloom, S. R.; Calam, J. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br. J. Cancer 1993, 67, 1437-1439.
83. de Jong, M.; Rolleman, E. J.; Bernard, B. F.; Visser, T. J.; Bakker, W. H.; Breeman, W. A.; Krenning, E.P. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J. Nucl. Med. 1996, 37, 1388-1392.
84. Schally, A. V.; Nagy, A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur. J. Endocrinol. 1999, 141, 1-14.
85. Beaumier, P. L.; Venkatesan, P.; Vanderheyden, J. L.; Burgua, W. D.; Kunz, L. L.; Fritzberg, A. R.; Abrams, P. G.; Morgan, A. C. Jr. 186-Re radioimunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res. 1991, 51, 676-681.
86. Juweid, M. E.; Hajjar, G.; Stein, R.; Sharkey, R. M.; Herskovic, T.; Swayne, L. C.; Suleiman, S,; Pereira, M.; Rubin, A. D.; Goldenberg, D. M. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J. Nucl. Med. 2000, 41, 93-103.
87. Yang, L.; Berk, S. C.; Rohrer, S. P.; Mosley, R. T.; Guo, L.; Underwood, D. J.; Arison, B. H.; Birzin, E. T.; Hayes, E. C.; Mitra, S. W.; Parmar, R. M.; Cheng, K.; Wu, T. J.; Butler, B. S.; Poor, F,; Pasternak, A.; Pan, Y.; Silva, M.; Freidinger, R. M.; Smith, R. G.; Chapman, K.; Schaeffer, J. M.; Patchett, A. A. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc. Natl Acad. Sci. USA 1998, 95, 10836-10841.
88. Rochaix, P.; Delesque, K; Esteve, J. P.; Saint-Laurent, K; Voight, J. J.; Vaysse, N.; Susini, C.; Buscail, L. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum. Gene Ther. 1999, 10, 995-1008.
89. Vernejoul, F.; Faure, P.; Benali, N.; Cause, D.; Tiraby, G.; Pradayrol, L.; Susini, C.; Buscail, L. Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res. 2002, 62, 6124-6131.
90. Lahorte, C. M.; Vanderheyden, J. L.; Steinmetz, N.; Van De Wiele, C.; Dierckx, R. A.; Siegers, G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur. J. Nucl. Med. Mol. Imaging 2004, 6, 887-919.
91. 99mTc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res. 2002, 8, 2766-2774.
92. 99mTc-HYNIC Annexin-V imaging of primary head and neck carcinoma. Nucl. Med. Commun. 2004, 25, 259-263.
93. 99mTc-rh-Annexin V in tumour-apoptosis detection [abstract]. Eur. J. Nucl. Med. Mol. Imaging 2003, 30(Suppl. 2), S167.
94. Li, S.; Peck-Radosavljevic, M.; Koller, E.; Koller, F.; Kaserer, K.; Kreil, A.; Kapiotis, S., Hamwi, A., Weich, H. A.; Valent, P.; Angelberger, P.; Dudczak, R.; Virgolini, I. Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int. J. Cancer 2001, 91, 789-796.
95. Li, S.; Peck-Radosavljevic, M.; Kienast, O.; Preitfellner, J.; Hamilton, G., Kurtaran, A.; Pirich, C.; Angelberger, P.; Dudczak, R. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann. Oncol. 2003, 14, 1274-1277.
96. 165): Biodistribution, Safety and Radiation Dosimetry in Patients with Pancreatic Carcinoma. QJNMMI 2004, 48, 198-206.
97. Li, L.; Wartchow, C. A.; Danthi, S. N.; Shen, Z.; Dechene, N.; Pease, J.; Choi, H. S.; Doede, T.; Chu, P.; Ning, S.; Lee, D. Y.; Bednarski, M. D.; Knox, S. J. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 1215-1227.